WASHINGTON — Though the vast majority of specialty physicians know what biosimilars are, their knowledge about these emerging medications falls short, according to a survey by the Biosimilars Forum. Of 1,201 U.S. physicians polled, 76.8% had heard the term biosimilars within the previous month, the Biosimilars Forum said Tuesday. Yet respondents exhibited five key gaps
HOLZKIRCHEN, Germany — Sandoz aims to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020. The Novartis division said Monday that the new biosimilars will emerge from “an aggressive regulatory submissions strategy” of 11 product filings that began last year and will run through 2017. Plans also call for an
DEVENS, Mass. — Bristol-Myers Squibb has completed a major expansion of its biologics facility in Devens, Mass. The drug maker said the $280 million project will spur development of the company’s growing portfolio of biologics medicines. With the expansion, the 89-acre Devens campus received two new buildings: a biologics development building for designing processes for
Biosimilars offer tremendous promise for millions of Americans suffering from cancer, rheumatoid arthritis or other diseases, offering lower-cost and highly effective alternatives to costly reference product drugs, also known as biologics. Biosimilars have been approved and prescribed effectively for close to a decade in nations across Europe and in Australia, offering patients increased access to
WASHINGTON — Zarxio (filgrastim), a cancer treatment from Sandoz Inc., has become the first biosimilar product approved in the United States. The Food and Drug Administration announced its approval of Zarxio, a biosimilar to Neupogen, an oncology product from Amgen Inc., on Friday. The move is being hailed as a watershed event that paves the
